The impact of heterogeneity on the comparison of survival times.

  title={The impact of heterogeneity on the comparison of survival times.},
  author={Martin Schumacher and M. Olschewski and C. Schmoor},
  journal={Statistics in medicine},
  volume={6 7},
We consider several sources of heterogeneity in a clinical trial with patients' survival time as the main response criterion: differences in prognosis which can be attributed to a latent or ignored prognostic factor; differences in treatment efficacy in subgroups of patients, and differences in treatment combinations received by the patients. The impact of these types of heterogeneity on the treatment comparison is studied assuming a proportional hazards model. It is measured by the size and… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 19 extracted citations

Cancer Clinical Trials

Founding Editor, Rentchnick
Recent Results in Cancer Research • 1988
View 8 Excerpts
Highly Influenced

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…